Alembic Pharmaceuticals Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - Gross borrowings as of December 31, 2022, are Rs. 686 crores, slightly higher than Rs. 630 crores as of March 2022. - Cash on hand has increased to Rs. 146 crores from Rs. 61 crores in March 2022. - Net debt equity ratio improved to 0.10. - Management did not discuss any plans or intentions regarding fresh equity or debt issuance during the call. Thus, based on the available information, Alembic Pharmaceuticals does not indicate any new fundraising plans through debt or equity at this time.

- Alembic Pharmaceuticals is incurring capital expenditure related to new facilities, with commercialization expected to start from the current quarter onwards. - Annual run rate operating expenses for all new facilities are about Rs. 200 crores, with additional depreciation costs. - Hard assets amount to approximately Rs. 1,200 crores, with the rest being accumulated pre-operative expenses. - The new facilities include Onco, Onco-injectables, and oral solid dosage blocks. - Commercial supplies for the new oncology facility are expected to start this quarter; Jarod facility operations may commence in FY ’24 or beyond. - The company is focusing on R&D cost optimization and rationalization to offset incremental operating expenses from new plants. - Alembic plans to reduce R&D expenses by 15%-20% in the next year while progressing with strategic investments in injectables and other product segments.

- US business: Moderate growth expected despite pricing erosion; volume growth higher than revenue growth (~10% growth in rupee terms with significant price erosion). - New product launches and injectables expected to drive incremental growth. - API business: Anticipated to grow 10-15% annually, though Q4 may be lumpy due to big one-off orders. - International markets (excluding US): Consistent ~10% growth noted; new projects being added. - India business: Recorded 15% growth outperforming industry (10% growth), with strong segments being gynecology, anti-diabetics, ophthalmology, anti-infectives, and cough & cold. - New facilities expected to start commercialization adding to growth, but expenses from these may pressure profits in the short term. - Overall, $300-400 million US sales potential over 3-4 years, though timelines delayed by 2-3 years due to plant execution delays. - R&D spend to be optimized to improve cost efficiency.

- US business growth expected to be modest due to pricing erosion but new product launches and strong flu season contributed to 10% growth in Q3 FY23 (Page 6). - R&D expenses targeted to reduce by 15-20% in FY24 to improve efficiency amid US market challenges (Pages 9-10). - New facilities coming online will increase operating expenses, potentially pressuring profits in FY24 (Pages 11-12, 16). - EBITDA margins and profit outlook uncertain for the next two years due to costs related to new plants and market conditions (Page 12). - Long-term potential of US sales estimated around $300 to $400 million over next 3-4 years, but timelines pushed back by 2-3 years (Pages 15-16). - Domestic business showing strong growth and outperformance, which can aid overall profitability (Pages 3-4). - Overall organic growth expected from new facilities and product launches, with midterm focus on cost control to improve earnings.

- The company has not provided specific figures for the current or expected order book in the call. - Mentioned the injectable approvals are in early stages with only a few product approvals so far. - There is anticipation of a lot of bunching up of approvals from new plants over the next 12-24 months, indicating a backlog that will convert into commercial orders. - Alembic anticipates seeing a faster approval rate moving forward post-compliance and remediation activities. - API segment shows growth visibility with expectation of at least 10-15% growth year-on-year. - The CMO business in API is described as "lumpy," with some large orders coming intermittently, contributing to orderbook fluctuations. - Overall, while exact orderbook numbers are not disclosed, there is cautious optimism for growth driven by new plant approvals and increased commercialization activity in injectables and APIs.